Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15918970 | 0.77 | TSHR (0.34) | MEN1TSHRCYP2C19RAB9AKMT2A | |
| SCHEMBL3924964 | 0.73 | — | — | |
| SCHEMBL11531553 | 0.72 | CA2 (0.37) | MEN1KMT2ACA2CA9 | |
| SCHEMBL8344705 | 0.70 | CA2 (0.38) | MEN1KMT2ACA2CA9 | |
| SCHEMBL3920183 | 0.67 | CA9 (0.33) | CA2CA9 | |
| SCHEMBL15919084 | 0.67 | — | — | |
| SCHEMBL8306539 | 0.66 | MEN1 (0.37) | MEN1TSHRCYP2C19RAB9AKMT2A | |
| SCHEMBL11477363 | 0.66 | CA2 (0.33) | CA2CA9 | |
| Hydrochloric Acid SCHEMBL3990289 | 0.65 | CA9 (0.32) | CA2CA9 | |
| SCHEMBL3917904 | 0.63 | GAA (0.34) | CYP2C19CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534787-B2 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-19 | — | — | US | disclosed |
| US-20090099159-A1 | Method of Treating Diseases and Conditions Associated with an Altered Level of Amyloid Beta Peptides and New Enolcarboxamide Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-7393843-B2 | Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-01 | — | — | US | disclosed |
| US-20080139541-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BORNEMANN KLAUS | 2008-06-12 | — | — | US | disclosed |
| US-7375220-B2 | Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
| US-20060040928-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2006-02-23 | — | — | US | disclosed |
| US-20050277635-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040928-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | APP, BACE1, PSEN1 | MEN1 1341/4885TSHR 1312/4885CYP2C19 2151/4885 |
| US-20090099159-A1 | Method of Treating Diseases and Conditions Associated with an Altered Level of Amyloid Beta Peptides and New Enolcarboxamide Compounds | APP, BACE1, PSEN1 | MEN1 1341/4885TSHR 1312/4885CYP2C19 2151/4885 |
| US-20050277635-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | APP, BACE1, PSEN1 | MEN1 1341/4885TSHR 1312/4885CYP2C19 2151/4885 |
| US-20080139541-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | APP, BACE1, PSEN1 | MEN1 1379/4885TSHR 1372/4885CYP2C19 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.